imagem top

2023

ANUÁRIO DO HOSPITAL
DONA ESTEFÂNIA

CHULC LOGOlogo HDElogo anuario

IMPACT OF GENOMIC MEDICINE FOR CRITICAL ILL INFANTS: A RETROSPECTIVE STUDY OF A REFERENCE CENTER IN LISBON, PORTUGAL

Susana Lemos Ferreira1, Joana A. Catanho1, Mafalda Melo1, Sofia Nunes1, Rui Gonçalves1, Marta Amorim1, Diana Antunes1, Margarida Venâncio1, Ema Leal2, Ana Maia Pita2, Pedro Garcia2, Patrícia Rodrigues2, Isabel Barata2, Maria João Lage2, Daniel Virella2, Inês Carvalho1

1 - Serviço de Genética Médica, Centro Hospitalar e Universitário de Lisboa Central, Lisboa, Portugal
2 - Unidade de Cuidados Intensivos Neonatais, Centro Hospitalar e Universitário de Lisboa Central, Lisboa, Portugal

- 26ª Reunião Anual da Sociedade Portuguesa de Genética Humanas, reunião nacional, sob a forma de comunicação oral

Introduction: Congenital malformations and genetic disorders are a leading cause of infant morbidity and mortality in the developed world, particularly in critical ill infants. Aim: To investigate the prevalence of genetic disease in a level IV neonatal intensive care unit (NICU) by identifying and describing genetic diagnosis, testing methodologies, timing of diagnosis, and clinical utility.
Methods: A retrospective medical review of NICU patient referred for inpatient Genetics observation from 2019 to 2021. Results: In total 50 patients were referred to genetic evaluation. The main clinical indication for referral was multiple congenital anomalies (19/50, 38%), followed by neurological disease (12/50, 24%), isolated congenital anomaly (7/50, 14%), single system condition (7/50, 14%), and multisystem disease (5/50, 10%). In total 18 patients received a genetic diagnosis (36%) using a variety of methodologies. In 42% cases (21/50), genetic evaluation is still ongoing and 22% (11/50) were clinical discharged without a genetic diagnosis. Cytogenetic techniques were the first-tier test in 42% cases (21/50) with a diagnostic yield of 10% (2/21). Whole exome sequencing (WES) was applied in 52% (26/50), of which 73% (19/26) as a first-tier test, and 27% (7/26) as follow-up investigation. Globally, WES had a diagnostic yield of 46% (12/26). Other methodologies included: Sanger sequencing (6/50, 12%), MS-MLPA (1/50, 2%), 7-dehydrocholesterol (1/50, 2%) and PCR (1/50, 2%). The age at molecular diagnosis ranged between 36 days and 34 months. A significant majority of diagnosis were made after inpatient discharge (13/18, 72%). Additionally, 28% (5/18) infants received a genetic diagnosis during hospitalization that impacted clinical decision making. All cases received genetic counselling.
Conclusion: Genomic medicine has high diagnostic and clinical utility in critical ill patients, as it allows for an appropriate management, early decision-making, establishing patient prognosis and appropriate genetic counselling. Our study provides important data for further improvements to the genetic diagnostic odyssey of critical ill patients.

Palavras Chave: critical ill infants, WES, NICU, genomic medicine